Search results
Results from the WOW.Com Content Network
Pimobendan is indicated for the management of the signs of mild, moderate, or severe congestive heart failure in dogs due to clinical myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM); [1] [7] and for use with concurrent therapy for congestive heart failure (e.g.,furosemide, etc.) as appropriate on a case-by-case basis. [1]
On December 30, 2016 Boehringer Ingelheim completed a swap of their OTC business for Sanofi's animal health business. Merial is now owned by Boehringer Ingelheim and combined with their animal health business, Boehringer Ingelheim Vetmedica, to form Boehringer Ingelheim Animal Health.
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies , and the largest private one.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The organization provides services such as volunteer dog walking, litter box maintenance, and other pet care; a pet food pantry; foster care; and discounted veterinary services to its clients. In 2019, PAWS NY helped 275 people and their 387 pets across New York City [4] and in 2020, the organization was featured on The Weekend TODAY Show. [5]
In 1993, Boehringer Ingelheim took over the IMP shares of Genentech. Following Max Birnstiel's retirement in 1997, Kim Nasmyth became scientific director. In 2006, two institutes of the Austrian Academy of Sciences were opened in the vicinity of the IMP: the Institute of Molecular Biotechnology (IMBA) and the Gregor Mendel Institute (GMI). The ...
As of May 2013, Boehringer and Lilly had submitted applications for marketing approval to the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). [50] Empagliflozin was approved in the European Union in May 2014, [13] and was approved in the United States in August 2014.